ENTRY       D05868                      Drug
NAME        Sodium phenylbutyrate (JAN/USP);
            Buphenyl (TN)
PRODUCT     BUPHENYL (Horizon Therapeutics USA)
            OLPRUVA (Acer Therapeutics)
            PHEBURANE (Medunik USA)
  GENERIC   SODIUM PHENYLBUTYRATE (GLENMARK PHARMACEUTICALS)
            SODIUM PHENYLBUTYRATE (Par Pharmaceutical)
            SODIUM PHENYLBUTYRATE (Par Pharmaceutical)
            SODIUM PHENYLBUTYRATE (Sigmapharm Laboratories)
FORMULA     C10H11O2. Na
EXACT_MASS  186.0657
MOL_WEIGHT  186.1829
REMARK      Therapeutic category: 3999
            ATC code: A16AX03
            Product: D05868<JP/US>
            Product (mixture): D12439<US>
EFFICACY    Antihyperammonemic
  DISEASE   Deficiency of carbamylphosphate synthetase [DS:H00164]
            Deficiency of ornithine transcarbamylase [DS:H00187]
            Deficiency of argininosuccinic acid synthetase [DS:H00185]
            Urea cycle disorders [DS:H01398]
COMMENT     Active form of prodrug: Phenylacetate [CPD:C07086]
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             A ALIMENTARY TRACT AND METABOLISM
              A16 OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
               A16A OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
                A16AX Various alimentary tract and metabolism products
                 A16AX03 Sodium phenylbutyrate
                  D05868  Sodium phenylbutyrate (JAN/USP) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Genetic, Enzyme, or Protein Disorder: Replacement, Modifiers, Treatment
              Sodium Phenylbutyrate
               D05868  Sodium phenylbutyrate (JAN/USP)
            Therapeutic category of drugs in Japan [BR:br08301]
             3  Agents affecting metabolism
              39  Other agents affecting metabolism
               399  Miscellaneous
                3999  Others
                 D05868  Sodium phenylbutyrate (JAN/USP)
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D05868
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D05868
            Pharmacogenomic biomarkers [br08341.html]
             Germline mutations in genetic disorder treatments
              D05868
            Prodrugs [br08324.html]
             D05868
DBLINKS     CAS: 1716-12-7
            PubChem: 47207529
            ChEBI: 75316
            LigandBox: D05868
            NIKKAJI: J783.828J
ATOM        13
            1   Z   Na   13.8833  -28.3419 #+
            2   C8x C     8.1900  -28.3500
            3   C8x C     8.1900  -29.7500
            4   C8x C     9.4024  -30.4500
            5   C8x C    10.6149  -29.7500
            6   C8x C    10.6149  -28.3500
            7   C8y C     9.4024  -27.6500
            8   C1b C     9.4024  -26.2502
            9   C1b C    10.5980  -25.5598
            10  C1b C    11.7852  -26.2452
            11  C6a C    12.9766  -25.5572
            12  O6a O    14.1659  -26.2439 #-
            13  O6a O    12.9767  -24.1503
BOND        12
            1     2   3 2
            2     3   4 1
            3     4   5 2
            4     5   6 1
            5     6   7 2
            6     2   7 1
            7     7   8 1
            8     8   9 1
            9     9  10 1
            10   10  11 1
            11   11  12 1
            12   11  13 2
///
